Skip to main content

Table 1 Baseline characteristics of all eyes, regression, and persistent groups

From: Seven-year outcomes of combined treatment of anti-vascular endothelial growth factor with photodynamic therapy for polypoidal choroidal vasculopathy; according to polypoidal lesion regression

 

Total

Regression

Persistent

p-value

No. of eyes

33

17 (51.5%)

16 (48.5%)

 

Women

9 (27.3%)

3 (17.6%)

6 (37.5%)

0.259

Age (years)

66.0 ± 10.9

65.6 ± 9.1

66.4 ± 12.8

1.000

Diabetes

7 (21.2%)

4 (23.5%)

3 (18.8%)

1.000

Hypertension

18 (54.5%)

8 (47.1%)

10 (62.5%)

0.491

BCVA (logMAR)

0.58 ± 0.36

0.56 ± 0.57

0.59 ± 0.41

0.958

CFT (µm)

342.6 ± 199.1

345.6 ± 124.8

339.6 ± 117.1

0.897

PED vol (mm3)

0.36 ± 0.45

0.35 ± 0.54

0.38 ± 0.34

0.305

GLD (µm)

3737 ± 1095

3676 ± 1206

3801 ± 998

0.709

  1. BCVA = best corrected visual acuity, CFT = central foveal thickness, PED = pigment epithelial detachment, GLD = greatest linear dimension, SMH = submacular hemorrhage